2.50
Hdl Handle:
http://hdl.handle.net/10541/72558
Title:
Does growth hormone cause cancer?
Authors:
Jenkins, P J; Mukherjee, Annice; Shalet, Stephen M
Abstract:
The ability of GH, via its mediator peptide IGF-1, to influence regulation of cellular growth has been the focus of much interest in recent years. In this review, we will explore the association between GH and cancer. Available experimental data support the suggestion that GH/IGF-1 status may influence neoplastic tissue growth. Extensive epidemiological data exist that also support a link between GH/IGF-1 status and cancer risk. Epidemiological studies of patients with acromegaly indicate an increased risk of colorectal cancer, although risk of other cancers is unproven, and a long-term follow-up study of children deficient in GH treated with pituitary-derived GH has indicated an increased risk of colorectal cancer. Conversely, extensive studies of the outcome of GH replacement in childhood cancer survivors show no evidence of an excess of de novo cancers, and more recent surveillance of children and adults treated with GH has revealed no increase in observed cancer risk. However, given the experimental evidence that indicates GH/IGF-1 provides an anti-apoptotic environment that may favour survival of genetically damaged cells, longer-term surveillance is necessary; over many years, even a subtle alteration in the environmental milieu in this direction, although not inducing cancer, could result in acceleration of carcinogenesis. Finally, even if GH/IGF-1 therapy does result in a small increase in cancer risk compared to untreated patients with GH deficiency, it is likely that the eventual risk will be the same as the general population. Such a restoration to normality will need to be balanced against the known morbidity of untreated GH deficiency.
Affiliation:
Departments of Endocrinology, St Bartholomew's Hospital, London, UK. p.j.jenkins@qmul.ac.uk
Citation:
Does growth hormone cause cancer? 2006, 64 (2):115-21 Clin. Endocrinol. (Oxf)
Journal:
Clinical Endocrinology
Issue Date:
Feb-2006
URI:
http://hdl.handle.net/10541/72558
DOI:
10.1111/j.1365-2265.2005.02404.x
PubMed ID:
16430706
Type:
Article
Language:
en
ISSN:
0300-0664
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorJenkins, P J-
dc.contributor.authorMukherjee, Annice-
dc.contributor.authorShalet, Stephen M-
dc.date.accessioned2009-07-06T12:00:46Z-
dc.date.available2009-07-06T12:00:46Z-
dc.date.issued2006-02-
dc.identifier.citationDoes growth hormone cause cancer? 2006, 64 (2):115-21 Clin. Endocrinol. (Oxf)en
dc.identifier.issn0300-0664-
dc.identifier.pmid16430706-
dc.identifier.doi10.1111/j.1365-2265.2005.02404.x-
dc.identifier.urihttp://hdl.handle.net/10541/72558-
dc.description.abstractThe ability of GH, via its mediator peptide IGF-1, to influence regulation of cellular growth has been the focus of much interest in recent years. In this review, we will explore the association between GH and cancer. Available experimental data support the suggestion that GH/IGF-1 status may influence neoplastic tissue growth. Extensive epidemiological data exist that also support a link between GH/IGF-1 status and cancer risk. Epidemiological studies of patients with acromegaly indicate an increased risk of colorectal cancer, although risk of other cancers is unproven, and a long-term follow-up study of children deficient in GH treated with pituitary-derived GH has indicated an increased risk of colorectal cancer. Conversely, extensive studies of the outcome of GH replacement in childhood cancer survivors show no evidence of an excess of de novo cancers, and more recent surveillance of children and adults treated with GH has revealed no increase in observed cancer risk. However, given the experimental evidence that indicates GH/IGF-1 provides an anti-apoptotic environment that may favour survival of genetically damaged cells, longer-term surveillance is necessary; over many years, even a subtle alteration in the environmental milieu in this direction, although not inducing cancer, could result in acceleration of carcinogenesis. Finally, even if GH/IGF-1 therapy does result in a small increase in cancer risk compared to untreated patients with GH deficiency, it is likely that the eventual risk will be the same as the general population. Such a restoration to normality will need to be balanced against the known morbidity of untreated GH deficiency.en
dc.language.isoenen
dc.subjectCanceren
dc.subjectCancer Recurrenceen
dc.subject.meshAcromegaly-
dc.subject.meshAdult-
dc.subject.meshAnimals-
dc.subject.meshChild-
dc.subject.meshChild Development-
dc.subject.meshColorectal Neoplasms-
dc.subject.meshHuman Growth Hormone-
dc.subject.meshHumans-
dc.subject.meshInsulin-Like Growth Factor I-
dc.subject.meshNeoplasm Recurrence, Local-
dc.subject.meshNeoplasms-
dc.subject.meshNeoplasms, Multiple Primary-
dc.subject.meshRisk Factors-
dc.titleDoes growth hormone cause cancer?en
dc.typeArticleen
dc.contributor.departmentDepartments of Endocrinology, St Bartholomew's Hospital, London, UK. p.j.jenkins@qmul.ac.uken
dc.identifier.journalClinical Endocrinologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.